Search results for "Hepatocellular"

showing 10 items of 885 documents

Associated Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Registry: What Have We Learned?

2020

In 2007, the first associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure was performed in Regensburg, Germany. ALPPS is a variation of two-stage hepatectomy to induce rapid liver hypertrophy allowing the removal of large tumors otherwise considered irresectable due to a too small future liver remnant. In 2012, the international ALPPS registry was created, and it now contains more than 1,000 cases. During the past years, improved patient selection and refinements in operative techniques, in particular, less invasive approaches such as Partial ALPPS, Tourniquet ALPPS, Ablation-assisted ALPPS, Hybrid ALPPS or Laparoscopic or Robotic approaches, have resu…

medicine.medical_specialtymedicine.medical_treatmentLess invasivePortal vein ligationReviewResection03 medical and health sciences0302 clinical medicineCarcinomaHepatectomyHumansMedicineRegistriesPerihilar CholangiocarcinomaRandomized Controlled Trials as TopicTwo-stage hepatectomyALPPS registryHepatologyPortal Veinbusiness.industryCarcinoma hepatocellularLiver NeoplasmsGastroenterologymedicine.diseaseSurgeryTreatment OutcomeBile Duct NeoplasmsLiver030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyALPPSOutcome dataHepatectomyPerihilar cholangiocarcinomabusinessGut and Liver
researchProduct

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

2013

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth an…

medicine.medical_treatmentCancer TreatmentGene ExpressionApoptosisPharmacologyBiochemistryTargeted therapy0302 clinical medicineMolecular Cell Biology0303 health sciencesSulfonamidesMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionQLiver NeoplasmsRDrug SynergismGenomicsSorafenib3. Good healthGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineLiver cancermedicine.drugResearch ArticleBiotechnologySignal TransductionSorafenibNiacinamideProgrammed cell deathCarcinoma HepatocellularScienceBlotting WesternBiologyMolecular Genetics03 medical and health sciencesCell Line TumorGastrointestinal TumorsmedicineIn Situ Nick-End LabelingHumansneoplasmsBiology030304 developmental biologyCell ProliferationDNA PrimersHuman liver cancer Apoptosis Sorafenib Celecoxib anti-proliferative effectsCell growthGene Expression ProfilingPhenylurea CompoundsComputational BiologyCancers and NeoplasmsHepatocellular CarcinomaChemotherapy and Drug Treatmentmedicine.diseaseMicroarray Analysisdigestive system diseasesGene expression profilingApoptosisCell cultureCelecoxibPyrazolesGenome Expression AnalysisPLoS ONE
researchProduct

Preoperative oral practices and incidence of postoperative complications in hospital medical-surgical procedures: A meta-analysis

2023

 Oral decay prior to a hospital medical-surgical procedure is a risk factor for the development of postoperative complications. However, perioperative oral practices as a protective factor have not been studied. This review aims to evaluate the effectiveness of perioperative oral practices in the reduction of risk of developing postoperative complications in in-hospital medical surgical procedures. This review and meta-analysis was conducted according to Cochrane guidelines. Medline, Scopus, Scielo, and Cochrane were consulted. Articles of the previous 10 years concerning adult patients undergoing perioperative oral practices prior to hospital medical-surgical procedures, were included. Dat…

meta-analysisoral lichen planussystematic reviewOtorhinolaryngologyhepatitisSurgeryhepatocellular carcinomaGeneral DentistryUNESCO:CIENCIAS MÉDICASMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Usefulness of multiplanar reconstruction with multislice computed tomography to assess hepatocellular carcinoma response after transcatheter arterial…

2008

multislice computed tomographyhepatocellular carcinomatranscatheter arterial chemoembolization
researchProduct

A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B

2018

Background Host genetic modifiers of the natural history of chronic hepatitis B (CHB) remain poorly understood. Recently, a genome-wide association study (GWAS)-identified polymorphism in the STAT4 gene that contributes to the risk for hepatocellular carcinoma (HCC) was shown to be associated with the full spectrum of hepatitis B virus (HBV) outcomes in Asian patients. However, the functional mechanisms for this effect are unknown and the role of the variant in modulating HBV disease in Caucasians has not been investigated. Aims To determine whether STAT4 genetic variation is associated with liver injury in Caucasian patients with CHB and to investigate potential mechanisms mediating this e…

musculoskeletal diseases0301 basic medicinemedicine.medical_specialtyGenome-wide association studymedicine.disease_cause03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingimmune system diseasesInternal medicinemedicineGenetic predispositionPharmacology (medical)skin and connective tissue diseasesHepatitis B virusHepatologybusiness.industryGastroenterologyhemic and immune systemsHepatologyHepatitis Bmedicine.disease030104 developmental biologyHepatocellular carcinomaImmunologyInterleukin 12030211 gastroenterology & hepatologyViral hepatitisbusinessAlimentary Pharmacology & Therapeutics
researchProduct

MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver

2016

nonalcoholic fatty liver diseaseHepatologyHepatocellular carcinomabusiness.industrySettore MED/12 - GASTROENTEROLOGIAFatty liverGastroenterologyLocus (genetics)medicine.diseaseHepatocellular carcinoma; nonalcoholic fatty liver disease03 medical and health sciences0302 clinical medicineN/A030220 oncology & carcinogenesisHepatocellular carcinomaNonalcoholic fatty liver diseasemedicineCancer research030211 gastroenterology & hepatologybusinessDigestive and Liver Disease
researchProduct

Hepatocellular cancer cell lines, Hep-3B and Hep-G2 display the pleiotropic response to resveratrol and berberine

2022

Purpose Human carcinoma cells with different p53 status exposed to a combination of bioactive substances, resveratrol and berberine, revealed different responses in cell viability via p53-dependant apoptosis pathway activation. Materials and methods Using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay, we investigated various and opposing effects in hepatocellular carcinoma cells, Hep-G2 and Hep-3B with different p53-status. Results Cells decreased in viability after treatment with dose-dependent concentrations of resveratrol and berberine. Hep-3B p53 mutants were more sensitive in comparison to the p53 wild type Hep-G2 cell line. A syne…

p53 statusViability isobologramBerberine and resveratrol treatmentsHuman hepatocellular cancer cellsHep-G2 and Hep-3B cell LinesAdvances in Medical Sciences
researchProduct

Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma

2018

Hepatocellular carcinoma (HCC) is a highly malignant tumor that responds very poorly to existing therapies, most probably due to its extraordinary inter- and intra-tumor molecular heterogeneity. The modest therapeutic response to molecular targeted agents underlines the need for new therapeutic approaches for HCC. In our study, we took advantage of well-characterized human HCC cell lines, differing in transcriptomic subtypes, DNA mutation and amplification alterations, reflecting the heterogeneity of primary HCCs, to provide a preclinical evaluation of the specific heat shock protein 90 (HSP90) inhibitor AUY922 (luminespib). Indeed, HSP90 is highly expressed in different tumor types, but it…

p53MaleCancer ResearchCellTranscriptome0302 clinical medicineHCCbeta CateninAged 80 and overLuminespibAUY922Liver NeoplasmsHep G2 CellsSorafenibMiddle AgedUp-RegulationGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyCaspases030220 oncology & carcinogenesisHepatocellular carcinomaFemaleNUPR1medicine.drugAdultSorafenibCarcinoma Hepatocellularβ-CateninMice NudeAntineoplastic AgentsSmall Molecule Libraries03 medical and health sciencesDownregulation and upregulationIn vivoCell Line TumormedicineHSP90AnimalsHumansHSP90 Heat-Shock ProteinsAgedCell growthbusiness.industryMcl-1IsoxazolesResorcinolsHCCSmedicine.diseasedigestive system diseasesMutationCancer researchTranscriptomebusinessInternational Journal of Cancer
researchProduct

Delivery of shNupr1 plasmid by solid lipid nanoparticles reduces the expression of Nupr1 gene in hepatocellular carcinoma cells

2015

shNupr1 plasmid gene delivery hepatocellular carcinoma
researchProduct

Reply to: Sorafenib in clinical practice: Evidence-based use or abuse?

2012

sorafenibhepatocellular carcinoma
researchProduct